Identification of cisplatin‐resistance related genes in head and neck squamous cell carcinoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Resistance to cisplatin is a major obstacle to successful treatment of head and neck squamous cell carcinoma (HNSCC). To investigate the molecular mechanism of this resistance, we compared the gene expression profiles between the cisplatin‐sensitive SCC cell lines (Sa‐3, H‐1 and KB) and the cisplatin‐resistant cell lines established from them (Sa‐3R, H‐1R and KB‐R) using Affymetrix U133 Plus 2.0 microarray. We identified 199 genes differentially expressed in each group. To identify important functional networks and ontologies to cisplatin resistance, the 199 genes were analyzed using the Ingenuity Pathway Analysis Tool. Fifty‐one of these genes were mapped to genetic networks, and we validated the top‐10 upregulated genes by real‐time reverse transcriptase‐polymerase chain reaction. Five novel genes, LUM, PDE3B, PDGF‐C, NRG1 and PKD2, showed excellent concordance with the microarray data. In 48 patients with oral SCC (OSCC), positive immunohistochemical staining for the five genes correlated with chemoresistance to cisplatin‐based combination chemotherapy. In addition, the expression of the five genes predicted the patient outcomes with chemotherapy. Furthermore, siRNA‐directed suppressed expression of the five genes resulted in enhanced susceptibility to cisplatin‐mediated apoptosis. These results suggested that these five novel genes have great potential for predicting the efficacy of cisplatin‐based chemotherapy against OSCC. Global gene analysis of cisplatin‐resistant cell lines may provide new insights into the mechanisms underlying clinical cisplatin resistance and improve the efficacy of chemotherapy for human HNSCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 10×
“In addition, several microarray studies have been performed to identify genes with altered expression in HNSCC.2,14 From these studies, numerous genes have been associated with the development and progression of head and neck cancer, some of which will be used as novel chemotherapeutic targets to treat or prevent HNSC…”
BackgroundInfluentialHartmann, L. C., Lu, K. H., Linette, G. P., Cliby, W. A., Kalli, K. R., Gershenson, D., Bast, R. C., Stec, J., Iartchouk, N., Smith, D. I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1673 · Cited by 141 · cited 1×
“identified a gene expression profile in acute lymphoblastic leukemia and ovarian cancer that contained a paucity of transcripts commonly implicated in resistance.(15,16) However, we have identified some drug resistant related genes; ABCC1,(17,18) AKR1C1,(19,20) AKR1C2,(19,20) CYP1B1,(21) SGPP1,(22) and CDKN2A(23) (Sup…”
Background
Cited by
Longati, P., Jia, X., Eimer, J., Wagman, A., Witt, M.-R., Rehnmark, S., Verbeke, C., Toftgård, R., Löhr, M., & Heuchel, R. L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-95 · Cited by 394
Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets
Ahmad, F., Murata, T., Shimizu, K., Degerman, E., Maurice, D., & Manganiello, V (2015) · Oral Diseases · doi:10.1111/odi.12275 · Cited by 184
“…cells, exhibited increased expression of PDE3B compared with parental cell lines (Yamano et al, 2010), and, as assessed by PDE3B immunohistochemical staining, PDE3B expression levels were significantly higher in the tumors unresponsive to cisplatin than in responsive tumors (Yamano et al, 2010).”
BackgroundThe Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
Lucas, L. M., Dwivedi, V., Senfeld, J. I., Cullum, R. L., Mill, C. P., Piazza, J. T., Bryant, I. N., Cook, L. J., Miller, S. T., Lott, J. H., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000381 · Cited by 70
“There are multiple reports in which an ERBB4 ligand stimulates malignant phenotypes and chemoresistance of tumor cells (Yamano et al., 2010; Mill et al., 2011a; Sato et al., 2013; Dahlhoff et al., 2014; Riese and Cullum, 2014; Mota et al., 2017; Segers et al., 2020).”
BackgroundDillon, M. T., Grove, L., Newbold, K. L., Shaw, H., Brown, N. F., Mendell, J., Chen, S., Beckman, R. A., Jennings, A., Ricamara, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1539 · Cited by 16
Metadata
- Authors
- Yamano, Y., Uzawa, K., Saito, K., Nakashima, D., Kasamatsu, A., Koike, H., Kouzu, Y., Shinozuka, K., Nakatani, K., Negoro, K., Fujita, S., & Tanzawa, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-08-24
- Volume
- 126
- Issue
- 2
- Pages
- 437-449
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2022152336
- Cited by
- 91
- References
- 2
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.